256 results on '"Kosmider, Suzanne"'
Search Results
2. Initial Assessment of Resectability of Colorectal Cancer Liver Metastases Versus Clinical Outcome
3. Availability and accessibility of services to address financial toxicity described by Australian lung cancer patients and healthcare professionals
4. Real world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer.
5. Value in care: The contribution of supportive care to value‐based lung cancer services—A qualitative semistructured interview study
6. Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases
7. Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer
8. Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status
9. Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data
10. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
11. Compliance with Therapeutic Goods Association prescribing information: weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer.
12. Emerging trends in the prediction of pathological tumour response in rectal cancer following neoadjuvant therapy
13. Current colorectal cancer chemotherapy dosing limitations and novel assessments to personalize treatments
14. Compliance with Therapeutic Goods Association prescribing information: weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer
15. How accurate are medical oncologists’ impressions of management of metastatic colorectal cancer in Australia?
16. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
17. Long-term survival outcomes following resection of lung metastases (LM) from a colorectal primary.
18. Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer
19. Biology and Clinical Implications of Fecal Occult Blood Test (FOBT) Screen-Detected Colorectal Cancer
20. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer
21. The rapidly escalating cost of treating colorectal cancer in Australia
22. Variable implementation of optimal therapeutic strategies in metastatic colorectal cancer: Reviewing rates of liver resection and triplet chemotherapy across Australian hospitals as potential quality indicators.
23. Real‐world outcomes for neoadjuvant capecitabine versus infusional 5‐fluorouracil in the treatment of locally advanced rectal cancer
24. Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival
25. Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia
26. Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice
27. Stage dependent recurrence patterns and post-recurrence outcomes in non-metastatic colon cancer
28. Chemotherapy at the end of life in colorectal and pancreatic cancer: Real-world data and trends over time.
29. Serious hepatic complications of selective internal radiation therapy with yttrium-90 microsphere radioembolization for unresectable liver tumors
30. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer
31. Characteristics and outcomes for fecal occult blood test (FOBT) screen detected (SD) versus non-screen detected (NSD) colorectal cancer (CRC).
32. Outcomes of isolated distant lymph node metastases in colorectal cancer.
33. Impact of adjuvant chemotherapy and patient age on patterns of metastatic recurrence in stage III colorectal cancer.
34. Second primary cancers in patients with sporadic deficient mismatch repair (dMMR) colorectal cancer (CRC).
35. Initial experience of TAS-102 chemotherapy in Australian patients with chemorefractory metastatic colorectal cancer.
36. Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer.
37. Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation
38. Lymph node yield following colorectal cancer surgery
39. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies
40. Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer.
41. Use and impact of perioperative chemotherapy in patients with resectable colorectal cancer metastases.
42. Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia
43. CD8 + tumor‐infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival
44. Dose rounding of chemotherapy in colorectal cancer: An analysis of clinician attitudes and the potential impact on treatment costs
45. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
46. Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer
47. TOWARDS ESTABLISHING A NATIONAL COLORECTAL CANCER DATABASE: LESSONS LEARNT FROM BIO21 MOLECULAR MEDICINE INFORMATICS MODEL
48. Anticoagulation prophylaxis for central venous catheter-associated thrombosis in cancer patients: An Australian perspective
49. An incorrect diagnosis of metastatic colorectal cancer: The need for tissue diagnosis prior to treatment
50. Stage-based variation in the impact of colon cancer surveillance.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.